

Clinical Commentary Review

The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome

Joseph Butterfield, MD^{a,b}, and Catherine R. Weiler, MD, PhD^a Rochester, Minn

Mast cells (MCs) leave evidence of their presence and activation. Aside from increased numbers of MCs in tissues, this evidence includes detecting elevated serum levels of tryptase and discovering increased excretion of urinary metabolites of prostaglandin (PG) D₂, leukotriene (LT) C₄, and/or histamine. The importance of measuring these nontryptase mediator metabolites has largely gone unnoticed. We reviewed the utility of quantitating urinary levels of MC mediator metabolites in systemic mastocytosis (SM) and MC activation disorders and summarized the relative production of these mediators by MCs and other cell types. Quantitation of urinary n-methyl histamine, 2,3-dinor-11βPGF_{2α}, and LTE₄ offers a simple, noninvasive avenue to monitor their constitutive release as well as contemporaneous discharge during MC activation as well as supporting a diagnosis of SM. These increases can occur independently of or in addition to raised levels of tryptase. Quantitation of these mediator metabolites potentially offers targets for therapeutic intervention. Synthesis of PGD₂, a product nearly exclusively of MCs, can be controlled with aspirin, histamine increase by H1 and H2 receptor blockade, and LTC₄ by a 5-LO inhibitor or LT receptor antagonist. Although other sources are reported, the increase in MC numbers in SM supports this cell as the predominant origin of all 3 mediators. © 2020 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2020;■:■-■)

Key words: Systemic mastocytosis; Mast cell activation syndrome; Histamine; N-Methyl histamine; Leukotriene C₄; Leukotriene E₄; Prostaglandin D₂; 2,3-Dinor-11β-PGF_{2α}

Systemic mastocytosis (SM), a clonal disorder of tissue infiltration by excessive mast cell (MC) numbers, and mast cell activation syndrome (MCAS), a disorder of episodic, or, more rarely, chronic symptoms due to release of an overabundance of

MC mediators, continue to challenge the diagnostic and therapeutic expertise of clinicians.

The criteria for the definition of SM have resulted from the collaborative work of experts in the fields of allergic disorders, hematology, gastroenterology, dermatology, and pathology. As currently specified, the major criterion, bone marrow infiltration by compact clusters of 15 or more MCs in tryptase-stained specimens, and one of the minor criteria: (1) serum baseline tryptase level of ≥ 20 ng/mL; (2) the presence of the Asp816Val mutation in the MC KIT receptor; (3) abnormal MC morphology, a fibroblastic or spindled appearance, in $>25\%$ of bone marrow MCs; and (4) abnormal MC phenotype as indicated by the presence of CD25 on bone marrow MC, are required for the diagnosis of SM. Alternatively, in the absence of the major criterion, SM can be diagnosed by the presence of 3 minor criteria.

MCAS is currently defined by 3 criteria: (1) episodic symptoms involving 2 or more organ systems consistent with those produced by sudden release of MC mediators; (2) an increase of the serum tryptase level above baseline values by 20% plus an additional 2 ng/mL; and (3) relief or prevention of attacks by medications that block production of MC mediators or that block their receptors. A subset of patients with mast cell activation (MCA) has more chronic day-to-day symptoms without episodic spells.

Primary MCAS occurs in patients with clonal MC disorders such as SM and in a subset of patients with evidence of an abnormal clone of MC (presence of KIT mutation and/or of the presence of the CD25 marker), but who do not meet the criteria for SM. This latter group is termed monoclonal MCA disorder. Secondary MCAS occurs in patients with IgE-mediated allergic disorders, anaphylaxis, inflammatory, or autoimmune disorders. The third group, idiopathic MCAS, occurs in patients who have no evidence for a clonal MC disorder, or any defined allergic, inflammatory, or autoimmune cause.¹⁻⁴

MC mediators are released during episodes of MCA. Patients may have a history of anaphylaxis in addition to the many other symptoms they experience.⁵⁻⁷ Some MC mediators are preformed and others are newly synthesized on stimulation.⁸⁻¹⁶ These mediators induce the symptoms associated with MC degranulation and activation.¹⁶⁻²¹ Serum tryptase, histamine metabolites, prostaglandin (PG) metabolites, and leukotriene (LT) metabolites are validated markers of MCA and degranulation.²² MCs can also synthesize and secrete numerous other mediators that are not commonly measured in the clinical laboratory and have yet to be incorporated in the definition of SM or MCAS.^{23,24}

Tryptase, one of the preformed mediators,^{25,26} has a defined diagnostic value for different MC disorders.²⁷⁻²⁹ A serum

^aDivision of Allergic Diseases, Mayo Clinic, Rochester, Minn

^bThe Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minn

No funding was received for this work.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication October 2, 2019; revised February 18, 2020; accepted for publication February 19, 2020.

Available online ■■

Corresponding author: Joseph Butterfield, MD, Mayo Clinic, 200 SW 1st Street, Rochester, MN 55905. E-mail: Butterfield.joseph@mayo.edu. 2213-2198

© 2020 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2020.02.021>

Abbreviations used

AA- Arachidonic acid
AERD- Aspirin-exacerbated respiratory disease
CI- Confidence interval
DAO- Diamine oxidase
FMLP- N-Formylmethionine-leucyl-phenylalanine
HDC- Histidine decarboxylase
HNMT- Histamine N-methyltransferase
LC-MS/MS- Liquid chromatography-tandem mass spectrometry
LT- Leukotriene
MC- Mast cell
MCA- Mast cell activation
MCAS- Mast cell activation syndrome
MIAA- N-Methylimidazole acetic acid
N-MH- N-Methylhistamine
NSAID- Nonsteroidal anti-inflammatory drug
PAF- Platelet activating factor
PG- Prostaglandin
PGDS- Prostaglandin D synthase
SM- Systemic mastocytosis
ULTE ₄ - Urinary LTE ₄

tryptase level above 20 ng/mL is one of the minor diagnostic criteria for SM,^{23,30} and an increase in serum tryptase by a minimum of 20% above baseline plus 2 ng/mL is considered a marker of MCA.^{1,2,26,31,32} There are a number of disadvantages in relying solely on serum tryptase for diagnosing MCA. Serum tryptase requires a blood sample collection ideally within 1 to 4 hours of a suspected MCA spell. This in turn necessitates an emergency department visit where the test might not be available or offered or where the physician is unwilling to obtain the sample.

Additional approaches to evaluate acute MCA are needed. Assessment of the production of validated urinary MC mediator metabolites offers a supplementary approach.²² Urine samples can be collected noninvasively by patients at their homes to monitor baseline conditions as well as contemporaneously after a suspected MCA spell. For this purpose a "mail-in" kit can be sent to the patient's home. It contains a urine specimen container, a serum tube for tryptase measurement, and a cold pack for shipping plus mailing instructions. The urine sample is mailed to the laboratory by overnight express for testing. Samples are stable if kept refrigerated or frozen. For sample accrual for acute symptoms, patients are instructed to initially empty the bladder and then to obtain a "fresh" urine specimen as well as a serum tryptase sample between 1 and 4 hours after an episode. Samples are kept refrigerated until mailed by overnight delivery in a container containing a cold pack. These samples supplement the results of tryptase quantitation; however, because of the unreliability of the emergency physician's ordering of tests, notably tryptase, required by patients, the urinary tests do provide measures of 3 of the 4 commonly quantitated MC mediators.

Three validated urinary mediators are currently available for testing in clinical laboratories. They include the histamine metabolite N-methylhistamine (N-MH) (methyl imidazole acetic acid is an available test in Europe but is not offered by any of the major testing labs in the United States), the PGD₂ metabolite 2,3-dinor-11 β PGF_{2 α} , and the cysteinyl LT metabolite LTE₄. One limitation of this approach is the lack of consensus for defining the level of increase in those mediators that would be

consistent with an MCA event; however, increased excretions of N-MH and 11 β PGF_{2 α} have been correlated with bone marrow findings in SM and have been helpful in guiding therapy for MCAS (see below). A second concern has been that, although these mediators are mainly produced by MCs, other cellular sources have been reported, albeit often from *in vitro* studies using nonphysiologic stimuli or experimental conditions.

For all of these assays, no dietary limitations are necessary. Avoidance of zileuton is required for baseline assessment of LTE₄, and avoidance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is needed for quantitation of baseline levels of 2,3-dinor-11 β PGF_{2 α} . In situations in which samples are collected acutely, there is no need or worth of medication avoidance as symptoms are already occurring.

The purposes of this article are to review the available literature regarding the generation and quantitation of those mediators, give some perspective to their production by non-MCs, examine their value in clinical practice, and suggest avenues for research to improve their utility in MC disorders.

HISTAMINE AND HISTAMINE METABOLITES

Histamine (2-[4-imidazolyl]-ethylamine) is synthesized from L-histidine by histidine decarboxylase (HDC). MCs and basophils each store comparably large amounts of histamine in their secretory granules, whereas other cell types synthesize and secrete histamine, but do not store it intracellularly. MCs and basophils release histamine when they are induced to degranulate.^{33,34} Histamine can also be produced by commensal bacteria colonizing mucosal surfaces.³⁵ Certain foods contain histamine.³⁶ Although it is frequently stated that certain foods induce nonallergic histamine release, evidence for this is scant.^{37,38} Histamine can be a contaminant of spoiled foods as in scombroid poisoning.³⁹

Once released, plasma histamine is metabolized rapidly (half-life 1-2 minutes)^{40,41} via 2 enzymatic pathways. The first pathway uses histamine N-methyltransferase (HNMT) and the second uses diamine oxidase (DAO). Approximately 70% of histamine is metabolized by HNMT to N-MH, which is then metabolized further by monoamine oxidase to N-methylimidazole acetic acid (MIAA).^{34,41} Both N-MH and MIAA can be measured in serum, plasma, and urine. HNMT is found in tissues throughout the body and is particularly important in the central nervous system and bronchial epithelium, where it is the only known histamine metabolizing enzyme.³⁴ The action of HNMT can be impaired by concurrent use of monoamine oxidase inhibitors.⁴²

The second enzymatic pathway uses DAO for histamine catabolism. DAO is a membrane glycoprotein primarily located in the kidney and colon. It is released on stimulation to oxidatively deaminate histamine and other substrates. DAO converts histamine to imidazole acetaldehyde that is then subsequently converted by aldehyde dehydrogenase to imidazole acetic acid and then conjugated with ribose phosphate.^{34,43}

Cells that contain and release histamine

MCs. The amount of histamine in MCs has been evaluated in a number of studies. The estimated amount of histamine is 1 to 5.5 pg/cell (lung MCs),⁴⁴ 3 to 8 pg/cell in lung, skin, intestinal tissues,^{10,45,46} and 3 pg/cell in mucosal MCs.¹⁰ The resting level of histamine in the skin is 5 nM. The release of histamine, LTC₄,

TABLE I. Histamine content in different human cells

	Location	Level	Reference
MCs	Lung	1.5-5 pg/cell	Paterson et al ⁴⁴
	Lung	2.5-10 pg/cell	Schulman et al ⁴⁵
	GI	3.0 pg/cell	Fox et al ¹⁰
	Skin	4.3 pg/cell	Benyon et al ⁴⁶
Basophils		0.66 pg/cell	Alcaniz et al ⁴⁹
		2.4 pg/cell	Sampson and Archer ⁴⁸
Platelets		Baseline 12.2 pmol/10 ⁹ platelets	Saxena et al ⁵⁰
		39 pmol/10 ⁹ after stimulation with PMA	
		8 ng/10 ⁹ platelets	Gill et al ⁵¹
Neutrophils		0.29 pg/cell	Alcaniz et al ⁴⁹

GI, Gastrointestinal; MC, mast cell; PMA, phorbol myristate acetate.

PGD₂, and thromboxane B₂ from human lung mast cells or lung fragments is not inhibited after a 24-hour incubation with 1 μ M dexamethasone.⁴⁷

Basophils. Basophils contain less histamine than do MCs, 0.66 $\pm$ 0.0779 pg of histamine/cell.⁴⁸ Basophil histamine release is slower (takes 20-30 minutes) than MC histamine release (takes 10 minutes). Incubation of human basophils with dexamethasone for a period of 4 to 24 hours inhibits IgE-dependent histamine release. Steroids, however, do not inhibit histamine release stimulated by other (nonphysiologic) agents f-met peptide (N-Formylmethionine-leucyl-phenylalanine [FMLP]), the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, and the calcium ionophore A23187. In patients with allergies, basophils show approximately 20-fold higher HDC expression (mRNA) than do neutrophils.⁴⁹

Neutrophils. Neutrophils do not store histamine, but they contain HDC. HDC induces histamine synthesis and is enzymatically active in neutrophils.⁴⁹ A total of 98% of neutrophils from patients with allergies or asthma are positive for HDC versus 10% from healthy donors.⁴⁹ Neutrophils from allergic donors exhibit approximately 4-fold higher HDC expression (mRNA) than neutrophils from normal donors.⁴⁹ The mean synthesized histamine in neutrophils is approximately 0.29 $\pm$ 0.036 pg/cell with 50% of the histamine content released after antigen stimulation (Table I).⁴⁹

Platelets. Unstimulated platelets contain small amounts of histamine, approximately 14.7 pmol/10⁹ platelets, whereas synthesis increases to about 36 pmol (approximately 4.01 ng) of histamine/10⁹ platelets after stimulation with phorbol myristate acetate, a nonphysiologic activator of protein C kinase. The bulk of histamine remains cytoplasmic.⁵⁰ In another report, the amount of histamine in platelets was approximately 8 ng/10⁹ cells (Table I).⁴¹

Other cells. Eosinophils do not contain HDC and do not release histamine on antigen or lipopolysaccharide stimulation.⁴⁹

Histamine assays

Blood histamine. Plasma samples are better than serum samples for the measurement of blood histamine levels. Serum samples can result in falsely elevated histamine levels as a result of basophil degranulation by complement activation during blood coagulation.⁵² The resting level of histamine in plasma is

0.5 to 2 nM.¹⁰ The half-life of intravenously infused histamine in normal volunteers is 1 to 2 minutes, reducing the practicality of this short-lived mediator as a clinically useful biomarker.^{41,53} Also, variability of the currently available assays for plasma histamine is problematic, further reducing its reliability as a measure of MC activation.⁵⁴

Urine histamine and its metabolites. Normal urinary clearance of histamine is 10 mcg/24 hours. In contrast, urinary histamine clearance in patients with SM is 150 mcg/24 hours. Measurement of urinary histamine is not an accurate measure of MCA. Only a small portion of the histamine that is released into the blood stream appears in the urine. Furthermore, inflammatory conditions in the bladder itself, such as interstitial cystitis, can result in an increased urinary histamine level.³⁵ The appropriate biomarkers of systemic histamine release from MCs or basophils are the histamine-specific metabolites, N-MH,⁵⁵⁻⁵⁷ and MIAA.⁵⁸⁻⁶¹

N-MH is obtained from the urine using solid phase extraction. The eluate is subsequently analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).⁶² Either 24-hour urine collections or random "spot" urine samples can be used, as results are expressed as micrograms/gram creatinine (mcg/g creatinine). Normal excretion is age dependent: 0 to 5 years: 120 to 510 mcg/g creatinine; 6 to 16 years: 70 to 330 mcg/g creatinine; >16 years: 30 to 200 mcg/g creatinine (source: Mayo Medical Labs).

PROSTAGLANDIN D₂ (PGD₂)

PGD₂ is generated from arachidonic acid (AA) by the sequential actions first of either cyclooxygenase 1 or 2, to generate PGH₂. PGH₂ is subsequently metabolized by either the hemopoietic (H-) or lipocalin (L-) type of PGD synthase (PGDS). L-PGDS is expressed in both the central nervous system and cardiac tissue. H-PGDS is expressed by MCs, megakaryocytes and platelets, monocytes, dendritic cells, Th₂ lymphocytes, and lung endothelial cells. H-PGDS is not expressed in basophils.⁶³

Large amounts of PGD₂ are rapidly synthesized and secreted by MCs activated by Fc ϵ RI aggregation. Elevated levels of another PG metabolite, PGF₂, were reported during labor.⁶⁴ PGF₂ is synthesized by the luteal endometrium,⁶⁵⁻⁶⁷ gestational tissues,⁶⁸ human and primate granulosa cells,⁶⁹ and hepatocytes.⁷⁰ However, there are no data comparing the levels of

TABLE II. Prostaglandin D₂ production by different human cells

Cell type	Location and stimulus	Level	Reference
MCs	Human lung, anti-IgE	50-60 ng/10 ⁶ cells	Schleimer et al ⁷²
	Human lung, anti-IgE	8.6-36.2 ng/10 ⁶ cells	Lewis et al ⁷³
	Human intestine, anti-IgE	21.3 ng/10 ⁶ cells	Fox et al ¹⁰
	MC cultured from umbilical cord, anti-IgE	0.7 ng/10 ⁴ cells	Obata ⁷⁹
Basophils	Human, calcium ionophore A23187, anti-IgE, or opsonized zymosan	0	van der Donk et al ⁶³
	Human, anti-IgE	~0.17 ng/10 ⁶ cells	Ugajin et al ⁷⁵
Th ₂ cells	Human, anti CD3 + anti CD28	2-6 ng/10 ⁶ cells	Tanaka et al ⁷⁶
Dendritic cells	Monocyte-derived dendritic cells, calcium ionophore	<1% of the amount produced by MCs	Shimura et al ⁷⁷
Eosinophils	Sinusitis tissue-derived in AERD, lysyl aspirin	19.41 ng/10 ⁶ cells	Feng et al ⁷⁸

AERD, Aspirin-exacerbated respiratory disease; MC, mast cell.

PG metabolites produced by MCs and those produced by endometrial tissues.

L-PGDS in brain-endothelial cells from human brain capillaries synthesize PGD₂. Both the PGD₂ induced by endothelial cells and the exogenous PGD₂ added to human brain cell endothelial cultures are converted to 9 α ,11 β -PGF₂, a known potent vasoconstrictor.⁷¹

Cells that produce and release PGD₂

MCs. Anti-IgE challenge of human lung mast cells leads to the release of 50 to 60 ng of PGD₂ per 10⁶ cells.⁷² Skin MCs contain similar amounts. Dexamethasone does not inhibit release of PGD₂ from lung fragments or purified MCs that were activated by anti-IgE.⁷² Dispersed and concentrated human lung MCs (30%-70% pure) when stimulated with anti-IgE generate 8.6 to 36.2 ng PGD₂/10⁶ cells.⁷³ The release of mediators by purified human lung MCs when stimulated with anti-IgE (as percentage of total metabolites) is 56% $\pm$ 6.4% for PGD₂ versus 21% $\pm$ 5.2% for LTC.⁷⁴ Airway lumen MCs in bronchoalveolar lavage generate 0.1 to 0.2 pg of PGD₂/cell. Umbilical cord MCs produce 0.7 ng/10⁴ cells with anti-IgE stimulation (Table II). The production of PGD₂ by umbilical cord MCs is inhibited by indomethacin and aspirin.⁷⁹

Basophils. MCs release the most substantial quantities of PGD₂, whereas basophil studies either reported no PG release,⁶³ or very little PGD₂ production at 0.01 ng/10⁶ basophils after stimulation with anti-IgE.⁷⁵

Th₂ cells. PGD₂ can also be produced by Th₂ cells (2-6 ng/10⁶ cells) but not Th₁ cells (Table II).⁷⁶ There are no reports of Th₂ cell PG secretion in SM or MCAS.

Dendritic cells. Dendritic cells have hematopoietic PGDS. Dendritic cells could, therefore, be a source of PGD₂ in the skin. However, the amount of PGD₂ secreted by dendritic cells is $\leq$ 1% of the amount secreted by MCs and 20-fold less than the amount secreted by Th₂ cells.⁷⁷ Orally ingested niacin, as well as topically applied methyl nicotinate to the skin, results in release of PGD₂. However, the lack of an accompanying increase of histamine release has suggested that MCs are not the source of PGD₂ in these cases.^{80,81} This raises the possibility that dendritic cells are a source for PGD₂ released in this situation.

Eosinophils. Eosinophils from patients with aspirin-exacerbated respiratory disease (AERD) display increased levels of hematopoietic PGDS. This was evaluated by studying gene

expression from tissues and blood samples of those patients. The level of PGDS in AERD is much higher than that in asthmatics and other control subjects.⁸² Eosinophils purified from sinus tissue of patients with AERD had spontaneous release of increased amounts of PGD₂: 1513 pg/10⁵ cells compared with 826 pg/10⁵ cells in chronic hyperplastic eosinophilic sinusitis.⁸²

LEUKOTRIENE METABOLITES

LTC₄ is generated when AA is converted by 5-lipoxygenase to LTA₄. This is followed by the action of LTC₄ synthase, which conjugates LTA₄ with reduced glutathione to form bioactive LTC₄. Bioactive LTC₄ is then secreted and rapidly metabolized to LTD₄, which is then metabolized to LTE₄. LTC₄ is produced directly by activated MCs, basophils, eosinophils, dendritic cells, monocytes, and macrophages, and indirectly by transcellular metabolism when LTA₄ is transferred from a cell lacking LTC₄ synthase to one that has LTC₄ synthase such as platelets.⁸³ LTE₄ is used to monitor this pathway in plasma or urine. There is no diurnal variation of LTE₄ excretion.^{84,85}

Cells that produce LTC₄

MCs. LTC₄ constituted 21.5% $\pm$ 5.2% (anti-IgE) and 17% $\pm$ 4.1% (A23187) of total AA metabolites released after overnight incubation of purified human lung MCs with ³H-AA and subsequent stimulation.⁷⁴ Purified human lung MCs stimulated with anti-IgE release between 28 and 32 $\times$ 10⁻¹¹ LTD₄ mole equivalents per 10⁶ MCs.⁸⁶⁻⁸⁸ Purified human lung MCs produce over 20-fold more LTD₄ mole equivalents than do basophils (Table III).

Basophils. LT production by basophils (and eosinophils) is enhanced by preincubation with IL-3 or IL-5. Basophils are capable of generating LTC₄ in approximately the same quantities 52.7 $\pm$ 25.6 ng/10⁶ cells as eosinophils (46.5 $\pm$ 11.7 ng/10⁶ cells) (Table III).⁸⁹ Basophils rapidly synthesize LTC₄ within minutes on allergen binding to specific IgE. IL-5 renders basophils capable of producing large quantities of LTC₄ in response to C5a. Without the cytokine, C5a by itself induces only histamine release.⁹⁰

When basophils are pretreated with IL-3 at concentrations of only 0.01 to 1 unit/mL, they become responsive to C3a, releasing large amounts of histamine and also generating LTs.⁹¹

Eosinophils. Normodense eosinophils, maintained in culture with 10⁻¹¹ M granulocyte/macrophage colony-stimulating factor, in the presence of 3T3 fibroblasts, become responsive

TABLE III. Leukotriene C₄ release by different human cells

Cell	Source; stimulus	Level	Reference
MCs	Human lung MC; anti-IgE	28-32 × 10 ⁻¹¹ mole equivalents LTD ₄ /10 ⁶ cells	MacGlashan ⁸⁶ ; Schulman ⁸⁷ ; MacGlashan ⁸⁸
Basophils	Peripheral blood; anti-IgE	1.1-1.6 × 10 ⁻¹¹ mole equivalents LTD ₄ /10 ⁶ cells	Schulman ⁸⁷ ; MacGlashan ⁸⁸
	Peripheral blood; calcium ionophore	52.7 ± 25.6 ng/10 ⁶ cells	Mita ⁸⁹
Eosinophils	Peripheral blood; calcium ionophore	46.5 ± 11.7 ng/10 ⁶ cells	Mita ⁸⁹
	Hypodense; FMLP	26 ng/10 ⁶ cells	Owen ⁹²
	Hyper eosinophilic donors; calcium ionophore	69 ± 28 ng/10 ⁶ cells	Weller ⁹³
	Normal donors; calcium ionophore	38 ± 3 ng/10 ⁶ cells	Weller ⁹³
	Peripheral blood; calcium ionophore	~30 ng/10 ⁶ cells	Owen ⁹⁴

FMLP, N-Formylmethionine-leucyl-phenylalanine; MC, mast cell.

to transmembrane stimulation with FMLP by day 4 with a maximal effect by day 7. After 7 days of culture, hypodense eosinophils stimulated with 2 × 10⁻⁷ M FMLP generate 26 ng LTC₄/10⁶ cells.⁹² In another report, eosinophils from hyper-eosinophilic donors produced 69 ± 28 ng of LTC₄/10⁶ cells, whereas eosinophils from normal donors generated 38 ± 3 ng/10⁶ cells when stimulated with ionophore A23187 (Table III).⁹³

In other studies, purified peripheral blood eosinophils preincubated with cytochalasin B and stimulated in the presence of L-serine with 2.5 μM A23187 produced approximately 30 ng LTC₄/10⁶ cells, whereas preincubation of cells with FMLP produced a maximum of 8 ng LTC₄/10⁶ cells.⁹⁴

In addition to the response to calcium ionophore, the production of LTC₄ by eosinophils from normal donors when stimulated by naturally occurring soluble agonists has been examined. The stimulants have included FMLP, C5a, and platelet activating factor (PAF). Of these 3 agonists, only FMLP stimulated some production of LTC₄ by normal eosinophils. After priming with IL-3 or IL-5, eosinophils produced detectable amounts of LTC₄ in response to all 3 agents and generated at least 1 order of magnitude more LTC₄ in response to FMLP as compared with stimulation with C5a or PAF.⁹⁵

Platelets. Platelets generate LTC₄ via transcellular conversion of LTA₄ to LTC₄ with the percentages of platelet-adherent leukocytes correlating with systemic cysLT production in AERD.⁸³

SUMMARY

Taken together, these studies strongly suggest that, although other sources of these mediators exist, MCs are a major source for histamine, PGD₂, and LTE₄. In MCAS and SM, where the activity and/or numbers of MC can be greatly increased, the possible contribution of other cell types to significantly affect measured levels of these mediators becomes less credible. Furthermore, increased numbers of these other inflammatory cells in MCAS or SM are not consistently found. Urinary samples, either by 24-hour collection or more recently by random urine specimens, are noninvasive methods for sample accrual for MC mediators because results are currently given as “per” gram or milligram creatinine. Samples obtained contemporaneously with symptoms afford a window of opportunity to document if MC mediator release has occurred and if so which MC mediator(s) are responsible for acute symptoms.

UTILITY OF URINARY MEDIATORS IN THE DIAGNOSIS AND TREATMENT OF SM AND MCAS

General comment

A spot urine sample obtained during a period of clinical quiescence should be obtained to serve as a reference point for subsequent samples acquired during times of clinical symptoms. There are currently no dietary limitations necessary before routine urine sampling for mediator quantitation. If possible, avoidance of the following medications for sampling in baseline states includes zileuton (5-lipoxygenase inhibitor affecting levels of LTC₄ and excretion of LTE₄) and aspirin/NSAIDs (cyclooxygenase inhibitors affecting levels of PGD₂ and excretion of 2,3-dinor-11βPGF_{2α}).

Histamine measurements in SM and MCAS. A high level of histamine in patients with SM is well documented, and in patients with urticaria pigmentosa, both polymyxin B and codeine injected parenterally can cause generalized flushing accompanied by an increase in urinary histamine.⁹⁶ However, the plasma histamine level is not a reliable biomarker to screen patients for mastocytosis⁹⁷ as this level may be increased in other disorders such as metastatic gastric carcinoid.⁹⁸ Rather, measurements of urinary histamine metabolites such as N-MH and MIAA have demonstrated clinical utility in diagnosing SM.^{57,99-101} These studies did not report any correlations between elevated urine N-MH levels and symptoms of MCA, perhaps because urine was not reliably collected during the acute period. Urinary excretion of histamine metabolites (NMH or MIAA) has been used in diagnostic algorithms to predict the likelihood of SM in patients lacking skin lesions.¹⁰²⁻¹⁰⁴ In one of these studies, receiver operating characteristic curves for tryptase, MIAA, and N-MH were examined. When all patients with a tryptase <10 μg/L were excluded, the areas under the curves for MIAA and N-MH were 0.92 (95% confidence interval [CI], 0.87-0.97) and 0.92 (95% CI, 0.87-0.98), respectively.¹⁰⁴ For patients with documented SM, urinary N-MH was significantly different between c-kit D816V positive and negative patients. N-MH excretion greater than about twice the upper limit of normal (>400 μg/g Cr) corresponded with high degree for the bone marrow presence of atypical MCs, MC aggregates, and c-kit mutation. N-MH excretion also correlated with serum tryptase values.¹⁰⁵

Treatment of symptoms in SM with antihistamines has shown approximately equal effectiveness of azelastine and chlorpheniramine, though azelastine was superior to chlorpheniramine in suppressing skin responses to histamine and morphine sulfate and in suppressing pruritus.¹⁰⁶ Control of SM symptoms with

cromolyn sodium or the combination of chlorpheniramine and cimetidine is approximately equal.¹⁰⁷ Interestingly, terfenadine and loratadine have been reported to inhibit spontaneous growth of HMC-1 cells, by primary neoplastic MC from human and canine donors, as well as growth by 2 canine MC lines, C2 and NI-1.¹⁰⁸ Ketotifen, reported to have H1 antihistamine and MC stabilizing properties *in vitro*, has been shown to be superior to hydroxyzine for symptomatic control in adult,¹⁰⁹ but not in pediatric mastocytosis.¹¹⁰ Neither ketotifen nor disodium cromoglycate significantly alters urinary excretion levels of histamine or MIAA.¹¹¹

A study of 25 patients showed that measurement of urinary N-MH was not as useful as measurement of serum tryptase or urinary 11β -PGF_{2 α} in diagnosing MCAS. In this study, baseline excretion of N-MH was increased in only 2 patients, both of whom had normal serum tryptase levels and excretion of 11β -PGF_{2 α} .¹¹²

PGD₂ in systemic mastocytosis and MCAS. In 1980, increased PGD₂ production was reported in 2 patients one of whom had a bone marrow biopsy consistent with mastocytosis and the second patient with a skin biopsy positive for increased perivascular MCs but with a negative bone marrow biopsy. Although plasma histamine concentrations were significantly increased in both patients during attacks, treatment with antihistamines alone was insufficient to control symptoms. Measured PGD₂ production was increased 120-fold above normal in the first patient, who succumbed to an attack, and 18-fold above normal in the second patient. In the second patient, inhibiting PGD₂ synthesis with aspirin (3.9 g/day) reduced excretion of the PGD₂ metabolite by 80% to 85%, and in addition to use of antihistamine, resulted in symptomatic improvement and prevention of the hypotensive episodes.^{113,114} In another study (46 urine samples from 17 biopsy-confirmed patients with SM), the urine PGD₂ metabolite PGD-M was increased above normal by as much as 300% in patients in whom excretion of N-methylhistamine was normal.¹¹⁵ Mean urinary excretion of the PGD₂ D-ring metabolite tetranor PGD-M was also significantly higher ($P < .01$) in patients with SM compared with controls (37.2 vs 11.5 ng/mg Cr), with 65% of 17 patients with SM showing elevated levels. The clinical sensitivity of 11β -PGF_{2 α} (>1000 ng/24 h) alone for diagnosis of SM was determined to be 53%.¹⁰⁰ Another report demonstrated that 24-hour urinary 11β -PGF_{2 α} excretion >3500 ng/day corresponded to a high degree with bone marrow biopsies positive for atypical MCs, the presence of aggregates, the *c-kit* mutation, and correlated with serum tryptase levels.¹⁰⁵

Aspirin, an inhibitor of cyclooxygenase, has been used to successfully treat symptoms from excessive PGD₂ release in SM.¹¹⁶⁻¹¹⁹ High doses of aspirin, 3.9 to 5.2 g/day (serum salicylate levels of 20-30 mg/dL), were used by Roberts et al^{117,119} to suppress baseline and MC activation-associated PGD₂ synthesis. Other studies have also shown the beneficial effect of aspirin (doses 750 mg/day to approximately 4 g/day) in SM.^{120,121}

In a study referred to above, of 25 patients with MCAS, only 2 had elevated N-MH values, whereas elevated baseline levels of 24-hour urinary 11β -PGF_{2 α} excretion occurred in 17 patients,¹¹² compared with elevated levels of tryptase in 10 patients. In this study, treatment with aspirin at doses from 81 mg/day to 500 mg BID normalized urinary 11β -PGF_{2 α} excretion and

controlled symptoms. In another report of patients with MCAS in whom either baseline or episodic release of PGD₂ was documented, aspirin (doses of 325 mg/day to 975 mg BID) was effective at preventing symptoms whereas antihistamine treatment alone was ineffective.¹²²

Other studies have shown that during anaphylaxis the level of $9\alpha,11\beta$ -PGF₂ in urine (272 pg/mg Cr) was significantly higher than levels of healthy controls (82 pg/mg Cr).²⁰ This increase was not observed during bronchial asthma exacerbation (approximately 100 pg/mg Cr). After provocation, $9\alpha,11\beta$ -PGF₂ increased during the 0- to 3-hour period after challenge. Parallel evaluation of the levels of eosinophil-derived neurotoxin in these patients after anaphylaxis did not reveal any change, thereby suggesting that eosinophils were not the source of this mediator.²⁰

LTE₄ in systemic mastocytosis and MCAS. The mean urinary LTE₄ (ULTE₄) level in healthy children (103 ± 9 pg/mg Cr) exceeds that of healthy adults (80 ± 7 pg/mg Cr).¹²³ ULTE₄ measurement is a sensitive method to assay total body cysteinyl LT production and changes in production.¹²⁴

Patients with indolent SM both with high intensity of clinical symptoms ($P < .003$) and with low intensity of SM symptoms ($P < .037$) had significantly increased excretion of cysteinyl LTs than controls. Good correlation with urinary N-MH excretion ($r = 0.536$, $P = .005$) was also reported in this study.¹²⁵ Compared with a control group of patients with symptoms such as food intolerance, exercise-induced asthma, hives, angioedema, drug allergy, and others, the ULTE₄ was significantly elevated in patients with SM and correlated with 24-hour urine N-MH and serum tryptase, but not with urinary 11β -PGF_{2 α} .¹²⁶ The normal ULTE₄ measured by LC-MS/MS has been reported to be <104 pg/mg Cr (95th percentile), with a mean value of 97 pg/mg Cr for those with SM versus 50 pg/mg Cr for controls. In this study, the assay was 48% sensitive and 84% specific for SM. Furthermore, when combined with measurements of N-MH and 11β -PGF_{2 α} , the SM diagnostic sensitivity of the combined mediators increased to 97%.¹⁰⁰

Quantitation of ULTE₄ will likely be useful in the diagnosis of MCAS because studies have also shown increased excretion in anaphylactic reactions.¹²⁷ In the report of Ono et al²⁰ that reported increased production of PGD₂ in anaphylaxis, ULTE₄ (772 pg/mg Cr) was also significantly higher than levels found in bronchial asthma exacerbation (216 pg/mg Cr) or healthy controls (66 pg/mg Cr). The maximum increase occurred during 3 to 6 hours after anaphylaxis. ULTE₄ was higher in those with anaphylaxis who developed severe hypotension (863 pg/mg Cr) versus those without anaphylactic shock (552 pg/mg Cr). Significant correlation was found between the maximum LTE₄ and $9\alpha,11\beta$ -PGF₂ in patients with anaphylactic shock.²⁰

In exercise-induced anaphylaxis cases, LTE₄ reached a maximum 2 to 5 hours after exercise and returned to normal by hour 20. The maximum increase was 5.5- to 52-fold (median 19-fold $P < .01$). The LTE₄ and N-MH rose in parallel during exercise-induced anaphylaxis.¹¹⁵ This time course of increase and return to normal approximates that reported by Ono et al.²⁰

Areas for clarification and further study

To use urinary mediators in the diagnosis and treatment of MC disorders additional information will be helpful. For example, the minimal rise in urinary histamine, PG, and LT

mediators necessary to define an MCA event is not currently established. Because both MCs and basophils produce histamine, it is possible that both cell types contribute to elevations of this mediator; however, MCs are more numerous than basophils,¹²⁸ markedly so in MC disorders, and their histamine content is higher than in basophils, thereby making them the more likely source for histamine increases. However, to separate “MC events” from those that are “basophil events,” quantitation of not only serum tryptase but also urinary PGD₂ metabolites, neither of which is produced by basophils, could be useful. The contribution of dietary histamine to measured N-MH levels needs to be clarified. For all of these mediators, better knowledge of the time courses of the mediator rise and subsequent decrease could be enhanced by sampling of “spot” urines for MC mediator metabolites at different time points after an episode of MCA. Finally, spot sampling will allow us to better define normal urinary levels of these products in children and to associate specific mediator increases with pediatric MCA events.

SUMMARY

Although histamine, PGD₂, and LTC₄ can be produced by other cell types, the MC is the predominant source in disorders with increased MC numbers and/or MC activation. Urinary assays can now be performed on random urine specimens. They are a simple to obtain, noninvasive method to confirm constitutive or episodic release of MC mediators. This capability also serves to guide treatment for blocking mediator production, for example with cyclooxygenase inhibitors (PGs) and zileuton (LTs), or blocking mediator receptors with antihistamines or montelukast. To date, however, as valuable a diagnostic tool as are urinary mediators, these tests have not been incorporated in the definition of either SM or MCAS.

REFERENCES

- Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol* 2012;157:215-25.
- Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. *J Allergy Clin Immunol Pract* 2019;7:1125-1123.e1.
- Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. *N Engl J Med* 2015;373:1885-6.
- Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. *N Engl J Med* 1987;316:1622-6.
- Valent P, Horny H-P, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. *Int Arch Allergy Immunol* 2011;156:119-27.
- Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. *Blood* 2007;110:2331-3.
- Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, et al. AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management. *J Allergy Clin Immunol* 2019;144:883-96.
- Metcalfe DD, Kaliner M, Donlon MA. The mast cell. *Crit Rev Immunol* 1981;3:23-74.
- Schwartz LB. Enzyme mediators of mast cells and basophils. *Clin Rev Allergy* 1983;1:397-416.
- Fox CC, Dvorak AM, Peters SP, Kagey-Sobotka A, Lichtenstein LM. Isolation and characterization of human intestinal mucosal mast cells. *J Immunol* 1985;135:483-91.
- Schleimer RP, MacGlashan DW Jr, Peters SP, Pinckard RN, Adkinson NF Jr, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. *Am Rev Respir Dis* 1986;133:614-7.
- Schwartz LB. Mediators of human mast cells and human mast cell subsets. *Ann Allergy* 1987;58:226-35.
- Gurish MF, Austen KF. Different mast cell mediators produced by different mast cell phenotypes. *Ciba Found Symp* 1989;147:36-45.
- Schwartz LB. Mast cells: function and contents. *Curr Opin Immunol* 1994;6:91-7.
- Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiol Rev* 1997;77:1033-79.
- Levy JH. Biomarkers in the diagnosis of anaphylaxis: making nature disclose her mysteries. *Clin Exp Allergy* 2009;39:5-7.
- Castells M. Mast cell mediators in allergic inflammation and mastocytosis. *Immunol Allergy Clin North Am* 2006;26:465-85.
- Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. *Clin Exp Allergy* 2008;38:4-18.
- Misso NL, Aggarwal S, Thompson PJ, Vally H. Increases in urinary 9alpha, 11beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma. *Int Arch Allergy Immunol* 2009;149:127-32.
- Ono E, Taniguchi M, Mita H, Fukutomi Y, Higashi N, Miyazaki E, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. *Clin Exp Allergy* 2009;39:72-80.
- Lazarinis N, Bood J, Gomez C, Kolmert J, Lantz AS, Gyllfors P, et al. Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor. *J Allergy Clin Immunol* 2018;142:1080-9.
- Butterfield JH, Ravi A, Pongdee T. Mast cell mediators of significance in clinical practice in mastocytosis. *Immunol Allergy Clin North Am* 2018;38:397-410.
- Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation—or should it be mast cell mediator disorders? *Expert Rev Clin Immunol* 2019;15:639-56.
- Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. *J Allergy Clin Immunol* 2019;143:451.
- Schwartz LB. Tryptase: a clinical indicator of mast cell-dependent events. *Allergy Proc* 1994;15:119-23.
- Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. *Int Arch Allergy Immunol* 2019;180:44-51.
- Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. *Immunol Allergy Clin North Am* 2006;26:451-63.
- Sonneck K, Florian S, Mullauer L, Wimazal F, Fodinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. *Int Arch Allergy Immunol* 2007;142:158-64.
- Akin C, Soto D, Brittain E, Chhabra A, Schwartz LB, Caughey GH, et al. Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. *Clin Immunol* 2007;123:268-71.
- Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. *Am J Hematol* 2019;94:363-77.
- Valent P. Mast cell activation syndromes: definition and classification. *Allergy* 2013;68:417-24.
- Baretto RL, Beck S, Heslegrave J, Melchior C, Mohamed O, Ekbote A, et al. Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective. *Allergy* 2017;72:2031-4.
- O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. *J Allergy Clin Immunol* 2011;128:1153-62.
- Jones BL, Kearns GL. Histamine: new thoughts about a familiar mediator. *Clin Pharmacol Ther* 2011;89:189-97.
- Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. *Urology* 2006;68:702-6.
- Malone MH, Metcalfe DD. Histamine in foods: its possible role in non-allergic adverse reactions to ingestants. *N Engl Reg Allergy Proc* 1986;7:241-5.
- Kleine-Tebbe J. Basophil histamine release by freshly prepared food extracts. *Allergy Proc* 1993;14:265-358.
- Baenkler HW, Lux G, Oltsch H. Food-induced histamine release from gastric and duodenal mucosa. *Hepatogastroenterology* 1984;31:233-5.
- Morrow JD, Margolies GR, Rowland J, Roberts LJ II. Evidence that histamine is the causative toxin of scombroid-fish poisoning. *N Engl J Med* 1991;324:716-20.
- Ind PW, Brown MJ, Macquin IM, Lhoste FJM. Plasma concentration: effect study of histamine infused in normal subjects. *Agents Actions* 1982;12:12-5.

41. Church MK, Shute JK, Sampson AP. Mast cell-derived mediators in Middleton's allergy principles and practice. 6th ed. Philadelphia, PA: Mosby; 2003:189-212.
42. Boudikova-Girard B, Scott MC, Weinshilboum R. Histamine N-methyltransferase: inhibition by monoamine oxidase inhibitors. *Agents Actions* 1993; 40:1-10.
43. Lieberman P. The basics of histamine biology. *Ann Allergy Asthma Immunol* 2011;106(Suppl):S2-5.
44. Paterson NA, Wasserman SI, Said JW, Austen KF. Release of chemical mediators from partially purified human lung mast cells. *J Immunol* 1976;117: 1356-62.
45. Schulman ES, Kagey-Sobotka A, MacGlashan DW Jr, Adkinson NF Jr, Peters SP, Schleimer RP, et al. Heterogeneity of human mast cells. *J Immunol* 1983;131:1936-41.
46. Benyon RC, Lowman MA, Church MK. Human skin mast cells: their dispersion, purification, and secretory characterization. *J Immunol* 1987;138: 861-7.
47. Schleimer RP, Davidson DA, Peters SP, Lichtenstein LM. Inhibition of human basophil leukotriene release by antiinflammatory steroids. *Int Arch Allergy Appl Immunol* 1985;77:241-3.
48. Sampson D, Archer GT. Release of histamine from human basophils. *Blood* 1967;29:722-36.
49. Alcaniz L, Vega A, Chacon P, El Bekay R, Ventura I, Aroca R, et al. Histamine production by human neutrophils. *FASEB J* 2013;27:2902-10.
50. Saxena SP, Brandes LJ, Becker AB, Simons KJ, LaBella FS, Gerrard JM. Histamine is an intracellular messenger mediating platelet aggregation. *Science* 1989;243:1596-9.
51. Gill DS, Barradas MA, Fonseca VA, Gracey L, Dandona P. Increased histamine content in leukocytes and platelets of patients with peripheral vascular disease. *Am J Clin Pathol* 1988;89:622-6.
52. Keyzer JJ, Wolthers BG, Muskiet FA, Breukelman H, Kauffman HF, de Vries K. Measurement of plasma histamine by stable isotope dilution gas chromatography-mass spectrometry: methodology and normal values. *Anal Biochem* 1984;139:474-81.
53. Ind PW, Brown MJ, Lhoste FJ, Macquin I, Dollery CT. Concentration effect relationships of infused histamine in normal volunteers. *Agents Actions* 1982; 12:12-6.
54. Poli C, Laurichesse M, Rostan O, Rossille D, Jeannin P, Drouet M, et al. Comparison of two enzymatic immunoassays, high resolution mass spectrometry method and radioimmunoassay for the quantification of human plasma histamine. *J Pharm Biomed Anal* 2016;118:307-14.
55. Van Gysel D, Oranje AP, Vermeiden I, de Lijster de Raadt J, Mulder PG, van Toorenenbergen AW. Value of urinary N-methylhistamine measurements in childhood mastocytosis. *J Am Acad Dermatol* 1996;35:556-8.
56. Oranje AP, Mulder PG, Heide R, Tank B, Riezebos P, van Toorenenbergen AW. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. *Clin Exp Dermatol* 2002;27:502-6.
57. Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. *Am J Gastroenterol* 2002;97:3071-7.
58. Thom H, Richardson JE, Mitchell RG. The urinary excretion of 1-methylimidazole-4-acetic acid, a histamine metabolite, by healthy and asthmatic children. *Clin Sci Mol Med* 1973;45:193-8.
59. Trachtman H, Tejani A, Neumann JJ, Wolthers BG, Oosting E. Urinary histamine excretion in proteinuric states. *Nephron* 1987;47:12-6.
60. Hermann K, Hertenberger B, Ring J. Measurement and characterization of histamine and methylhistamine in human urine under histamine-rich and histamine-poor diets. *Int Arch Allergy Immunol* 1993;101:13-9.
61. Donker ML, van Doormaal JJ, van Doormaal FF, Kluin PM, van der Veer E, de Monchy JG, et al. Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. *Haematologica* 2008;93:120-3.
62. Martens-Lobenhoffer J, Neumann HJ. Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis. *J Chromatogr B Biomed Sci Appl* 1999;721:135-40.
63. van der Donk EM, Blok W, Kok PT, Bruijnzeel PL. Leukotriene C₄ formation by enriched human basophil preparations from normal and asthmatic subjects. *Prostaglandins Leukot Essent Fatty Acids* 1991;44:11-7.
64. Karim SM. Appearance of prostaglandin F₂-alpha in human blood during labour. *Br Med J* 1968;4:618-21.
65. Markiewicz L, Gupride E. C19 adrenal steroids enhance prostaglandin F₂ alpha output by human endometrium in vitro. *Am J Obstet Gynecol* 1988;159: 500-4.
66. Markiewicz L, Laufer N, Gupride E. In vitro effects of clomiphene citrate on human endometrium. *Fertil Steril* 1988;50:772-6.
67. Brumsted JR, Chapitis J, Deaton JL, Riddick DH, Gibson M. Prostaglandin F₂ alpha synthesis and metabolism by luteal phase endometrium in vitro. *Fertil Steril* 1989;52:769-73.
68. Mitchell MD, Chang MC, Chaiworapongsa T, Lan HY, Helliwell RJ, Romero R, et al. Identification of 9alpha,11beta-prostaglandin F₂ in human amniotic fluid and characterization of its production by human gestational tissues. *J Clin Endocrinol Metab* 2005;90:4244-8.
69. Dozier BL, Watanabe K, Duffy DM. Two pathways for prostaglandin F₂ alpha synthesis by the primate periovulatory follicle. *Reproduction* 2008;136:53-63.
70. Hayashi H, Fujii Y, Watanabe K, Urade Y, Hayaishi O. Enzymatic conversion of prostaglandin H₂ to prostaglandin F₂ alpha by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung. *J Biol Chem* 1989;264:1036-40.
71. Liston TE, Roberts LJ II. Transformation of prostaglandin D₂ to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F₂): a unique biologically active prostaglandin produced enzymatically in vivo in humans. *Proc Natl Acad Sci U S A* 1985;82:6030-4.
72. Schleimer RP, Schulman ES, MacGlashan DW Jr, Peters SP, Hayes EC, Adams GK III, et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. *J Clin Invest* 1983;71: 1830-5.
73. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ II. Prostaglandin D₂ generation after activation of rat and human mast cells with anti-IgE. *J Immunol* 1982;129:1627-31.
74. Peters SP, MacGlashan DW Jr, Schulman ES, Schleimer RP, Hayes EC, Rokach J, et al. Arachidonic acid metabolism in purified human lung mast cells. *J Immunol* 1984;132:1972-9.
75. Ugajin T, Satoh T, Kanamori T, Aritake K, Urade Y, Yokozeki H. FcepsilonRI, but not FcgammaR, signals induce prostaglandin D₂ and E₂ production from basophils. *Am J Pathol* 2011;179:775-82.
76. Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S, Nagata K. Cutting edge: differential production of prostaglandin D₂ by human helper T cell subsets. *J Immunol* 2000;164:2277-80.
77. Shimura C, Satoh T, Igawa K, Aritake K, Urade Y, Nakamura M, et al. Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D₂ in the skin. *Am J Pathol* 2010;176:227-37.
78. Feng X, Ramsden MK, Negri J, Baker MG, Payne SC, Borish L, et al. Eosinophil production of prostaglandin D₂ in patients with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol* 2016;138:1089-1097.e3.
79. Obata T, Nagakura T, Kanbe M, Masaki T, Maekawa K, Yamashita K. IgE-anti-IgE-induced prostaglandin D₂ release from cultured human mast cells. *Biochem Biophys Res Commun* 1996;225:1015-20.
80. Morrow JD, Parsons WG III, Roberts LJ II. Release of markedly increased quantities of prostaglandin D₂ in vivo in humans following the administration of nicotinic acid. *Prostaglandins* 1989;38:263-74.
81. Morrow JD, Awad JA, Oates JA, Roberts LJ II. Identification of skin as a major site of prostaglandin D₂ release following oral administration of niacin in humans. *J Invest Dermatol* 1992;98:812-5.
82. Higashi N, Taniguchi M, Mita H, Yamaguchi H, Ono E, Akiyama K. Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E₄ (LTE₄) and prostaglandin D₂ (PGD₂) metabolites. *Allergol Int* 2012;61: 393-403.
83. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. *Blood* 2012;119:3790-8.
84. Kumlin M, Stensvad F, Larsson L, Dahlen B, Dahlen SE. Validation and application of a new simple strategy for measurements of urinary leukotriene E₄ in humans. *Clin Exp Allergy* 1995;25:467-79.
85. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. *Allergy* 1997;52:124-35.
86. MacGlashan DW Jr, Schleimer RP, Peters SP, Schulman ES, Adams GK, Sobotka AK, et al. Comparative studies of human basophils and mast cells. *Fed Proc* 1983;42:2504-9.
87. Schulman ES, MacGlashan DW Jr, Schleimer RP, Peters SP, Kagey-Sobotka A, Newball HH, et al. Purified human basophils and mast cells: current concepts of mediator release. *Eur J Respir Dis* 1983;64(Suppl 128): 53-61.
88. MacGlashan DW Jr, Schleimer RP, Peters SP, Schulman ES, Adams GK, Newball HH, et al. Generation of leukotrienes by purified human lung mast cells. *J Clin Invest* 1982;70:747-51.
89. Mita H, Akiyama K, Hayakawa T, Yamada T, Ikeda Y, Shida T. Purification of human blood basophils and leukotriene C₄ generation following calcium ionophore stimulation. *Prostaglandins Leukot Essent Fatty Acids* 1993;49: 783-8.

90. Bischoff SC, Brunner T, deWeck AL, Dahinden CA. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. *J. Exp Med* 1990;172:1577-82.
91. Bischoff SC, de Weck AL, Dahinden CA. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. *Proc Natl Acad Sci U S A* 1990;87:6813-7.
92. Owen WF Jr, Petersen J, Austen KF. Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP. *J Clin Invest* 1991;87:1958-63.
93. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. *Proc Natl Acad Sci U S A* 1983;80:7626-30.
94. Owen WF Jr, Soberman RJ, Yoshimoto T, Sheffer AL, Lewis RA, Austen KF. Synthesis and release of leukotriene C4 by human eosinophils. *J Immunol* 1987;138:532-8.
95. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. IL-3 and IL-5 prime normal human eosinophils to produce leukotriene C4 in response to soluble agonists. *J Immunol* 1991;147:3855-61.
96. Sutter MC, Beaulieu G, Birt AR. Histamine liberation by codeine and polymyxin B in urticaria pigmentosa. *Arch Dermatol* 1962;86:217-21.
97. Friedman BS, Steinberg SC, Meggs WJ, Kaliner MA, Frieri M, Metcalfe DD. Analysis of plasma histamine levels in patients with mast cell disorders. *Am J Med* 1989;87:649-54.
98. Roberts LJ II, Marney SR Jr, Oates JA. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. *N Engl J Med* 1979;300:236-8.
99. Cho C, Nguyen A, Bryant KJ, O'Neill SG, McNeil HP. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. *Immun Inflamm Dis* 2016;4:64-9.
100. Lueke AJ, Meeusen JW, Donato LJ, Gray AV, Butterfield JH, Saenger AK. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: a marker of systemic mastocytosis. *Clin Biochem* 2016;49:979-82.
101. Ridell B, Olafsson JH, Roupe G, Swolin B, Granerus G, Rodger S, et al. The bone marrow in urticaria pigmentosa and systemic mastocytosis. Cell composition and mast cell density in relation to urinary excretion of tele-methylimidazoleacetic acid. *Arch Dermatol* 1986;122:422-7.
102. Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, Matito A, Jara-Acevedo M, Teodosio C, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. *Int Arch Allergy Immunol* 2012;157:275-80.
103. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. *Allergy* 2014;69:1267-74.
104. van Doormaal JJ, van der Veer E, van Voorst Vader PC, Kluin PM, Mulder AB, van der Heide S, et al. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. *Allergy* 2012;67:683-90.
105. Divekar R, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. *Allergy* 2015;70:1230-8.
106. Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. *J Allergy Clin Immunol* 1993;92:520-6.
107. Frieri M, Alling DW, Metcalfe DD. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. *Am J Med* 1985;78:9-14.
108. Hadzijušufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, et al. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. *Exp Hematol* 2010;38:896-907.
109. Povia P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. *J Int Med* 1991;229:475-7.
110. Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. *J Allergy Clin Immunol* 1989;83:866-70.
111. Mallet AI, Norris P, Rendell NB, Wong E, Greaves MW. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N-tau-methylimidazole acetic acid in urine of patients with mastocytosis. *Br J Clin Pharmacol* 1989;27:88-91.
112. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. *J Allergy Clin Immunol Pract* 2014;2:775-8.
113. Roberts LJ II, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. *N Engl J Med* 1980;303:1400-4.
114. Roberts LJ II, Sweetman BJ, Lewis RA, Folarin VF, Austen KF, Oates JA. Markedly increased synthesis of prostaglandin D2 in systemic mastocytosis. *Trans Assoc Am Physicians* 1980;93:141-7.
115. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ II. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. *J Invest Dermatol* 1995;104:937-40.
116. Kootte AM, Haak A, Roberts LJ. The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production. *Neth J Med* 1983;26:18-20.
117. Roberts LJ II. Recurrent syncope due to systemic mastocytosis. *Hypertension* 1984;6(Pt 1):285-94.
118. Butterfield JH, Kao PC, Klee GC, Yocum MW. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. *Mayo Clin Proc* 1995;70:481-7.
119. Roberts LJ II, Fields JP, Oates JA. Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope. *Trans Assoc Am Physicians* 1982;95:36-41.
120. Crawhall JC, Wilkinson RD. Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition. *Clin Invest Med* 1987;10:1-4.
121. Lorcerie B, Arveux I, Chauffert B, Dalac S, Lambert D, Martin F. Aspirin and systemic mastocytosis. *Lancet* 1989;2:1155.
122. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. *Int Arch Allergy Immunol* 2008;147:338-43.
123. Westcott JY, Maxey KM, MacDonald J, Wenzel SE. Immunoaffinity resin for purification of urinary leukotriene E4. Prostaglandins Other Lipid Mediat 1998;55:301-21.
124. Rabinovitch N. Urinary leukotriene E4. *Immunol Allergy Clin North Am* 2007;27:651-664.vii.
125. Raithe M, Zopf Y, Kimpel S, Naegel A, Molderings GJ, Buchwald F, et al. The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis. *J Physiol Pharmacol* 2011;62:469-72.
126. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. *Prostaglandins Other Lipid Mediat* 2010;92:73-6.
127. Denzlinger C, Haberl C, Wilmanns W. Cysteinyl leukotriene production in anaphylactic reactions. *Int Arch Allergy Immunol* 1995;108:158-64.
128. Riley JF. The Mast Cells. Edinburgh, UK: Livingstone; 1959.